Suppr超能文献

阴道用孕激素维持保胎治疗:随机试验的系统评价和荟萃分析

Vaginal progesterone for maintenance tocolysis: a systematic review and metaanalysis of randomized trials.

作者信息

Suhag Anju, Saccone Gabriele, Berghella Vincenzo

机构信息

Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Thomas Jefferson University Hospital, Philadelphia, PA.

Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy.

出版信息

Am J Obstet Gynecol. 2015 Oct;213(4):479-87. doi: 10.1016/j.ajog.2015.03.031. Epub 2015 Mar 19.

Abstract

OBJECTIVE

We sought to evaluate the efficacy of maintenance tocolysis with vaginal progesterone compared to control (placebo or no treatment) in singleton gestations with arrested preterm labor (PTL) in a metaanalysis of randomized controlled trials.

STUDY DESIGN

Searches were performed in MEDLINE, OVID, Scopus, ClinicalTrials.gov, and the Cochrane Central Register of Controlled Trials with the use of a combination of key words and text words related to "progesterone," "tocolysis," and "preterm labor" from 1966 through November 2014. We included all randomized trials of singleton gestations that had arrested PTL and then were randomized to maintenance tocolysis treatment with either vaginal progesterone or control (either placebo or no treatment). All published randomized studies on progesterone tocolysis were carefully reviewed. Exclusion criteria included maintenance tocolysis in women with preterm premature rupture of membrane, maintenance tocolysis with 17-alpha-hydroxyprogesterone caproate, and maintenance tocolysis with oral progesterone. The summary measures were reported as relative risks (RRs) with 95% confidence interval (CI). The primary outcome was preterm birth (PTB) <37 weeks.

RESULTS

Five randomized trials, including 441 singleton gestations, were analyzed. Women who received vaginal progesterone maintenance tocolysis for arrested PTL had a significantly lower rate of PTB <37 weeks (42% vs 58%; RR, 0.71; 95% CI, 0.57-0.90; 3 trials, 298 women). Women who received vaginal progesterone had significantly longer latency (mean difference 13.80 days; 95% CI, 3.97-23.63; 4 trials, 368 women), later gestational age at delivery (mean difference 1.29 weeks; 95% CI, 0.43-2.15; 4 trials, 368 women), lower rate of recurrent PTL (24% vs 46%; RR, 0.51; 95% CI, 0.31-0.84; 2 trials, 122 women), and lower rate of neonatal sepsis (2% vs 7%; RR, 0.34; 95% CI, 0.12-0.98; 4 trials, 368 women).

CONCLUSION

Maintenance tocolysis with vaginal progesterone is associated with prevention of PTB, significant prolongation of pregnancy, and lower neonatal sepsis. However, given the frequent lack of blinding and the generally poor quality of the trials, we do not currently suggest a change in clinical care of women with arrested PTL. We suggest instead well-designed placebo-controlled randomized trials to confirm the findings of our metaanalysis.

摘要

目的

在一项随机对照试验的荟萃分析中,我们试图评估与对照组(安慰剂或不治疗)相比,阴道用黄体酮维持治疗对单胎妊娠且早产临产(PTL)停止者的疗效。

研究设计

从1966年至2014年11月,在MEDLINE、OVID、Scopus、ClinicalTrials.gov和Cochrane对照试验中央注册库中进行检索,使用与“黄体酮”、“宫缩抑制”和“早产临产”相关的关键词和文本词组合。我们纳入了所有单胎妊娠且PTL停止、随后被随机分配接受阴道用黄体酮或对照组(安慰剂或不治疗)维持宫缩抑制治疗的随机试验。对所有已发表的关于黄体酮宫缩抑制的随机研究进行了仔细审查。排除标准包括胎膜早破早产妇女的维持宫缩抑制治疗、己酸17-α-羟孕酮维持宫缩抑制治疗以及口服黄体酮维持宫缩抑制治疗。汇总测量结果报告为相对风险(RRs)及95%置信区间(CI)。主要结局是孕周<37周的早产(PTB)。

结果

分析了5项随机试验,包括441名单胎妊娠者。接受阴道用黄体酮维持宫缩抑制治疗的PTL停止妇女,孕周<37周的PTB发生率显著较低(42%对58%;RR,0.71;95%CI,0.57 - 0.90;3项试验,298名妇女)。接受阴道用黄体酮的妇女潜伏期显著延长(平均差异13.80天;95%CI,3.97 - 23.63;4项试验,368名妇女),分娩时孕周更大(平均差异1.29周;95%CI,0.43 - 2.15;4项试验,368名妇女),复发性PTL发生率较低(24%对46%;RR,0.51;95%CI,0.31 - 0.84;2项试验,122名妇女),新生儿败血症发生率较低(2%对7%;RR,0.34;95%CI,0.12 - 0.98;4项试验,368名妇女)。

结论

阴道用黄体酮维持宫缩抑制治疗与预防PTB、显著延长妊娠以及降低新生儿败血症有关。然而,鉴于试验中经常缺乏盲法且总体质量较差,我们目前不建议改变对PTL停止妇女的临床治疗。相反,我们建议进行精心设计的安慰剂对照随机试验以证实我们荟萃分析的结果。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验